Achilles Therapeutics is a biopharmaceutical company developing precision T cell therapies that target clonal neoantigens. Neoantigens are protein markers unique to each individual that are present on the surface of a cancer cell and can be detected by the immune system. Our approach is based on the science of tumor evolution which allows us to leverage our bioinformatics platform - powered by artificial intelligence (AI) - to identify ‘clonal’ neoantigens that arise early in cancer development and are retained as each tumor continues to grow and mutate. By directing T cell therapies against clonal neoantigens, which are present on all cancer cells and are completely absent from normal cells, we can for the first time target every cancer cell without attacking healthy tissue.
AI-POWERED PRECISION CELL THERAPY
Driving a transformation in solid tumor cancer treatment by targeting clonal neoantigens present on all cancer cells to develop precision T cell therapiesMore Info +